SYBX
What one share of Synlogic holds
Pharmaceutical Preparations
We are a biopharmaceutical company that previously advanced novel therapeutics to transform the care of serious diseases. We focused on rare metabolic disorders, with our lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU).
Synlogic’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.05 |
| Cash and investments | $1.13 |
| Book value | $1.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$87.73 | $0.75 | −$64.03 | — | — |
| 2016 | — | −$18.91 | $1.33 | −$16.02 | — | — |
| 2017 | — | −$90.06 | $5.75 | −$75.02 | — | — |
| 2018 | — | −$30.42 | $3.55 | −$30.23 | — | $73.28 |
| 2019 | — | −$25.45 | $0.62 | −$38.00 | — | $72.94 |
| 2020 | — | −$24.77 | $0.17 | −$16.72 | — | $45.23 |
| 2021 | — | −$16.42 | $0.18 | −$14.34 | — | $31.69 |
| 2022 | — | −$13.83 | $0.15 | −$12.05 | — | $18.57 |
| 2023 | — | −$9.42 | $0.03 | −$7.97 | — | $3.57 |
| 2024 | $0.00 | −$1.92 | $0.00 | −$2.60 | — | $1.09 |
| 2025 | $0.00 | −$0.08 | $0.00 | −$0.35 | — | $1.01 |